Published On: Sat, May 13th, 2017

Broker Changes For Kite Pharma, Inc. (NASDAQ:KITE)


Recently stock market analysts have updated their consensus ratings on shares of Kite Pharma, Inc. (NASDAQ:KITE).

Most recent broker ratings

05/09/2017 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 91 price target on the stock.

05/09/2017 – Kite Pharma, Inc. was downgraded to “underperform” by analysts at Wedbush. They now have a USD 54 price target on the stock.

05/08/2017 – Kite Pharma, Inc. was downgraded to “market perform” by analysts at Raymond James.

05/08/2017 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 89 price target on the stock.

05/08/2017 – Kite Pharma, Inc. had its “neutral” rating reiterated by analysts at Cowen. They now have a USD 74 price target on the stock.

05/08/2017 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 90 price target on the stock.

04/03/2017 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 93 price target on the stock.

04/03/2017 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 100 price target on the stock.

04/03/2017 – Kite Pharma, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 101 price target on the stock.

03/13/2017 – Kite Pharma, Inc. was downgraded to “hold” by analysts at Standpoint Research.

03/06/2017 – Kite Pharma, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 95 price target on the stock.

03/03/2017 – Kite Pharma, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus.

03/02/2017 – Kite Pharma, Inc. had its “neutral” rating reiterated by analysts at BTIG Research.

03/02/2017 – Kite Pharma, Inc. was downgraded to “neutral” by analysts at Citigroup. They now have a USD 87 price target on the stock.

02/22/2017 – Wells Fargo began new coverage on Kite Pharma, Inc. giving the company a “outperform” rating.

Kite Pharma, Inc. has a 50 day moving average of 78.99 and a 200 day moving average of 60.50. The stock’s market capitalization is 4.27B, it has a 52-week low of 39.82 and a 52-week high of 88.58.

The share price of the company (NASDAQ:KITE) was up +0.51% during the last trading session, with a high of 75.77 and the volume of Kite Pharma, Inc. shares traded was 1006396.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).